New treatment options for cancer patients with Covid-19 (coronavirus)

Ovarian cancer treatment

Page last updated on 22nd December 2021

Three new Covid-19 treatments - molnupiravir, Ronapreve and sotrovimab - are now available to vulnerable people with coronavirus, including people who are being treated for cancer or have a weakened immune system.

Molnupiravir (brand name Lagevrio) is an antiviral medicine, which stops coronavirus growing and spreading in the body. Ronapreve (a combination of casirivimab and imdevimab) and sotrovimab (brand name Xevudy) are antibody treatments. 

These three treatments can help manage Covid-19 symptoms and lower the risk of serious illness. They will be offered on the NHS and through a new study to people with Covid-19 who are at highest risk of becoming seriously ill from the virus. 

Visit the NHS website to read more about these treatments.

How will these treatments help protect people at-risk from Covid-19?

Molnupiravir, Ronapreve and sotrovimab are being given to help protect those most at risk from coronavirus. Molnupiravir has been shown in clinical trials to reduce the risk of hospitalisation or death for at-risk, non-hospitalised adults with mild to moderate Covid-19 by 30% and Ronapreve reduced the risk by 70%. Access to these treatments will be significant for those who have compromised immune systems who may not be as well protected by Covid-19 vaccines as the general population.

Accessing molnupiravir, Ronapreve and sotrovimab from the NHS

People aged 12 and over who test positive for Covid-19 and are at highest risk of getting seriously ill can access molnupiravir, Ronapreve or sotrovimab directly from the NHS. This includes people who have:

  • Certain types of cancer
  • Had an organ, bone marrow or stem cell transplant recently
  • Had chemotherapy grades B and C in the last 12 months
  • Had radiotherapy in the last 6 months
  • An NHS doctor or specialist will let you know if you are eligible for treatment, should you test positive for Covid-19.

If you're eligible for treatment and test positive for Covid-19, the NHS will contact you within 24 hours of your PRC result. This will probably be by email, text or phone. They will give you more information and advise which treatment, if any, is right for you.

If you have not been contacted within 24 hours of a positive PCR test but you think you may be eligible for treatment, call your GP surgery or 111 - they can make an urgent referral if necessary.

The PANORAMIC study

A national study called ‘PANORAMIC’ is also recruiting around 10,000 UK patients at risk of serious illness from Covid-19 to have the opportunity to take molnupiravir at home. It is open to anyone in the UK, provided they:

  • Receive a positive PCR test 
  • Feel unwell with symptoms of Covid-19 that started in the last five days
  • Are aged 50 and over, or are between 18 and 49 with an underlying condition that puts them more at risk of severe Covid-19 - this includes people who have a weakened immune system due to disease (e.g. cancer) or treatment (e.g. chemotherapy).

If eligible, people who receive a positive PCR test will be contacted by the study team or a local healthcare professional, for example their GP, to sign up to the trial. People can also sign up themselves through the study’s website

You can read more about the study on GOV.UK.

Do you have any questions?

If you have any questions about the information above, please email us at info@ovarian.org.uk. We may not know the answer straight away, but we will do our best to find out. We will keep this page as up-to-date as possible with the latest news, information and advice about new treatments for ovarian cancer patients with Covid-19.